Where we concentrate capital.
Three focus areas drive every check we write. Each is a sector where our operating platform gives founders an unfair, durable advantage. Each is defined narrowly enough to stay honest, and broadly enough to catch the companies that do not fit neat categories.
Intelligent systems and enterprise infrastructure that redefine how the modern company operates.
Precision medicine, biotech, and digital health extending human potential at global scale.
Deeptech, climate, robotics, and emerging sciences challenging the status quo.
Intelligent systems for the companies that run the world.
Every meaningful enterprise workflow is being rewritten right now. The question is not whether AI will transform the modern company, but which companies will build the systems that do it, and which will still be standing when the dust settles. We back the ones building durable infrastructure rather than wrapping thin veneers around foundation models.
Our conviction rests on three observations. First, enterprise AI is an integration problem, not a model problem. Second, the companies that win will look more like infrastructure than like apps. Third, the moat is data, workflow depth, and regulatory trust, not parameter count.
That is where our operating platform matters most. Selling enterprise infrastructure is hard. Selling it into healthcare, finance, and regulated industries is harder. Our portfolio companies get a running start: direct relationships with the kind of buyers that would otherwise take two years to reach.
Extending human potential. Transforming care.
Healthcare is both the largest and the slowest market on earth. The slowness is not an accident. Biology is complex, regulation is heavy, and the cost of being wrong is measured in lives. That is exactly why the companies that get it right compound for decades.
We invest in precision medicine, computational biology, diagnostics, and the digital health platforms that connect them to patients and clinicians. We look for companies whose technical depth is real, whose clinical evidence is ahead of their marketing, and whose founders take the slowness seriously rather than pretending it away.
Our edge here is specific. We have spent two decades building software for regulated healthcare buyers. We understand HIPAA, FDA submissions, payer dynamics, and the operational realities of running clinical pilots. That is not something you can buy. It is not something you can consult your way into. It is context, built slowly.
The bets that unlock entirely new markets.
Frontier is the bucket most firms are too polite to have. It is where we put the companies that do not fit the comfortable categories: robotics at the edge of physical plausibility, climate technology at industrial scale, new materials, novel energy, aerospace, advanced manufacturing. The common thread is ambition that borders on audacity and science that is credible enough to be dangerous.
We are not trying to be a deeptech specialist. We are trying to back the two or three companies per cycle that could actually reshape an industry, and we are willing to hold them for a decade to find out. The check size adapts. The conviction does not.
This is the part of the portfolio where patience matters most. Growth curves are lumpy. Technical milestones beat quarterly metrics. Our cross spectrum structure is built for exactly this: we can enter early, stay through the valley, and write the growth round when the curve finally bends.
We would like to see what you are building.
founders@acigv.com